摘要
随着老年化和医学的发展,心力衰竭将成为21世纪心血管两大流行疾病之一。尽管随着β-受体阻滞剂,血管紧张素转换酶抑制剂(ACEI)、血管紧张素受体拮抗剂(ARB)甚至是基因重组药物等的面世,心力衰竭治疗的目的及方法有了全新的改变,但心力衰竭的诊断、预后判断仍具有相当大的局限性,目前多以临床评估为主。现对心力衰竭中相关生化指标的意义作一简要综述。
The 21st century will see a growing epidemic of heart failure. However, with the appearance of β-receptor blockers, ACEI, ARB even gene-recombination drugs, the aims and means of the treatment to prevent heart failure have altered greatly. The diagnosis and prognosis evaluation of heart failure are still limited to clinical analysis. This article briefly reviews the clinical significance of the detection of biomarkers in heart failure.
出处
《心血管病学进展》
CAS
2006年第6期764-766,共3页
Advances in Cardiovascular Diseases
